Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Lucentis (Ranibizumab) Market Expected to Grow Between 2025 And 2029?
In recent times, the market size for lucentis (ranibizumab) has experienced robust growth. The market is projected to expand from $3,538.57 million in 2024 to $3,741.97 million in 2025, demonstrating a compound annual growth rate (CAGR) of 5.7%. Factors contributing to this growth trend during the historic period include an increase in age-related macular degeneration (AMD), approval and insurance coverage from regulatory authorities, effective clinical results, strong brand identity and acceptance by doctors, the introduction of biosimilars, and price competition.
What Growth Rate Is Anticipated for the Lucentis (Ranibizumab) Market in the Coming Years?
In the ensuing years, the ranibizumab (lucentis) market is projected to witness robust growth, ultimately achieving a size of $4,633.35 million in 2029 with a compound annual growth rate (CAGR) of 5.5%. This increase during the forecasted period can be attributed to a number of factors such as the rising incidence of diabetic retinopathy (DR) and diabetic macular edema (DME), the sophistication in treatment protocols and combination therapies, demographic aging, elevated prevalence of retinal disorders, enhancement of market accessibility in nascent markets, continuous clinical studies, and emerging new indications. The forecast period will also see significant trends such as the shift towards dosing at longer intervals and ongoing treatment, the expanding use of biosimilars and alternate treatments, the escalation in custom medical approaches for retinal disorders, increasing requisition in the emerging markets due to enhancements in healthcare accessibility, and incorporation of digital health solutions in treatment surveillance.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19907&type=smp
Who Are the Leading Companies in the Lucentis (Ranibizumab) Market?
Major companies operating in the lucentis (ranibizumab) market include F.Hoffmann-La Roche Ltd, Novartis AG
What Are the Key Drivers of the Lucentis (Ranibizumab) Market?
The increasing prevalence of ocular disorders is anticipated to contribute to the surging growth of the Lucentis (ranibizumab) market. Conditions that hinder the normal functioning of eyes constitute what is termed as eye-related disorders. Aging, genetic predisposition, improper lifestyle habits including excessive screen time, sun exposure, smoking and unhealthy diet play a significant role in the increased prevalence of these disorders. Lucentis acts by blocking vascular endothelial growth factor (VEGF), which is linked to abnormal blood vessel growth and leakage in the retina, thereby resulting in conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). As stated by the National Eye Institute, a US governmental agency, by 2030, the number of blind Americans is expected to reach 2.2 million in 2024. As such, the expanding prevalence of ocular disorders is prompting growth of the Lucentis (ranibizumab) market. The Upward Trend in Healthcare Spending’s Effect on The Lucentis (Ranibizumab) Market
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19907&type=smp
What Are the Key Market Segments in the Lucentis (Ranibizumab) Industry?
The lucentis (ranibizumab)market covered in this report is segmented –
1) By Type: Single-use Prefilled Syringe; Single-use Glass Vial
2) By Application: Age-related Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion; Myopic Choroidal Neovascularization; Uveitis
3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
What Are the Latest Trends in the Lucentis (Ranibizumab) Market?
The prevailing trend in the Lucentis (ranibizumab) market is the creation of biosimilars that offer more cost-effective alternatives to the original branded product. Biosimilars are biological pharmaceuticals that are highly analogous to an already approved reference biologic in structure, effectiveness, and safety, with no significant clinical differences. For example, Formycon AG, a biotech firm based in Germany, and Bioeq AG, a biotech company from Switzerland, introduced their Lucentis (ranibizumab) biosimilar, called FYB201, in Canada and Switzerland in April 2024. Health Canada approved the biosimilar’s marketing under the name Ranopto, and Swiss Medic authorized it as Ranivisio. The approval and subsequent introduction of FYB201 aim to offer more economical treatment choices for patients with retinal disorders. The biosimilar works by inhibiting vascular endothelial growth factor A (VEGF-A), a protein causing abnormal blood vessel growth in the retina, leading to symptoms like swelling, leakage, and vision loss.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/lucentis-ranibizumab-global-market-report
What Are the Key Regional Markets in the Lucentis (Ranibizumab) Industry?
North America was the largest region in the lucentis (ranibizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19907
This Report Delivers Insight On:
1. How big is the lucentis (ranibizumab) market, and how is it changing globally?
2. Who are the major companies in the lucentis (ranibizumab) market, and how are they performing?
3. What are the key opportunities and risks in the lucentis (ranibizumab) market right now?
4. Which products or customer segments are growing the most in the lucentis (ranibizumab) market?
5. What factors are helping or slowing down the growth of the lucentis (ranibizumab) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model